Moreover, studies with oxaliplatin sensitive and resistant gastric cancer organoids revealed that CD133+ CSCs acquire resistance through METTL3-mediated m6A modification of PARP1 mRNA. This evidence concerns the gene PARP1 and gastric cancer.